Compare · HRMY vs JNJ
HRMY vs JNJ
Side-by-side comparison of Harmony Biosciences Holdings Inc. (HRMY) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HRMY and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $536.54B, about 299.8x HRMY ($1.79B).
- Over the past year, HRMY is down 9.0% and JNJ is up 44.8% - JNJ leads by 53.8 points.
- Both names hit the wire about 12 times in the past 4 weeks.
- JNJ has more recent analyst coverage (25 ratings vs 23 for HRMY).
- Company
- Harmony Biosciences Holdings Inc.
- Johnson & Johnson
- Price
- $32.11+3.85%
- $223.61+0.31%
- Market cap
- $1.79B
- $536.54B
- 1M return
- -1.46%
- -0.24%
- 1Y return
- -9.04%
- +44.77%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 12
- Recent ratings
- 23
- 25
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest HRMY
- Harmony Biosciences to Participate in Upcoming Investor Conferences
- SEC Form 4 filed by Director Germano Geno J
- SEC Form 3 filed by new insider Germano Geno J
- SEC Form 4 filed by Director Szyper Linda M
- SEC Form 4 filed by Director Philip Ron M
- SEC Form 4 filed by Director Graf R. Mark
- SEC Form 4 filed by Director Sabater Juan A.
- SEC Form 4 filed by Director Sender Gary
- CHIEF MEDICAL OFFICER Budur Kumar converted options into 18,750 shares and covered exercise/tax liability with 8,882 shares, increasing direct ownership by 69% to 24,115 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by CHIEF FINANCIAL OFFICER Reicin Glenn
Latest JNJ
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target